Helicos BioSciences, which is developing genetic analysis technologies for research and drug discovery uses, lowered its anticipated price range Wednesday. The revised price range is $10-$11, 25% below the midpoint of the original $13-$15 price range. UBS is the bookrunner on the deal.
